Intratracheal administration with TCs was found to reduce lung inflammation and tissue injury and improve the lung function in mechanical ventilation‐induced acute lung injury, through the maintenance of microvascular endothelial barrier function and production of vascular endothelial growth factor (VEGF) from TCs.7 This evidence concerns the gene VEGFA and acute lung injury.